Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease-Reference-Cited by-同舟云学术

Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease

Published:2006-02 Issue:2 Volume:64 Page:219-224
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Giraldi Francesca Pecori,Scaroni Carla,Arvat Emanuela,Martin Martina,Giordano Roberta,Albiger Nora,Leao Adriana A. S.,Picu Andreea,Mantero Franco,Cavagnini Francesco

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2265.2006.02452.x/fullpdf

Reference18 articles.

1. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

2. 4A.P. Heaney, M.R. Drange, and S. Melmed (2003 ) Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas (Cushing's disease) . 85th Annual Meeting of the Endocrine Society, OR7 -4 , Philadelphia, PA, USA.

3. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PPARG dysregulation as a potential molecular target in adrenal Cushing's syndrome;Frontiers in Endocrinology;2023-11-30

2. ACTH-dependent Cushing's syndrome;Endocrine Hypertension;2023

3. Nuclear Receptors as Regulators of Pituitary Corticotroph Pro-Opiomelanocortin Transcription;Cells;2020-04-07

4. The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome;Frontiers in Endocrinology;2019-05-21

5. Regulation of POMC and ACTH Secretion;Encyclopedia of Endocrine Diseases;2019